The First Long-Term Trial: THC Reduced Tourette Tics Over 6 Weeks
The first controlled long-term trial found that THC (up to 10 mg/day) significantly reduced tics in Tourette syndrome over 6 weeks, with no serious adverse effects, providing the strongest evidence yet for cannabinoid treatment.
Quick Facts
What This Study Found
In this 6-week randomized, double-blind, placebo-controlled trial, THC (up to 10 mg/day) produced significant improvements or trends toward improvement across multiple tic rating scales. Using patient self-ratings, there was a significant difference between THC and placebo across 10 treatment days. The overall ANOVA also demonstrated a significant difference (p=0.037).
Seven of 24 patients dropped out or were excluded, but only one due to side effects. No serious adverse effects occurred. This was the first controlled trial to demonstrate THC effectiveness for tics over a sustained treatment period rather than a single dose.
Key Numbers
Twenty-four patients enrolled, 17 completed. THC dose up to 10 mg/day. Treatment duration: 6 weeks with 6 assessment visits. Overall ANOVA p=0.037. One dropout due to side effects.
How They Did This
This was a randomized, double-blind, placebo-controlled parallel study. Twenty-four patients with Tourette syndrome (DSM-III-R criteria) were treated for 6 weeks with up to 10 mg/day THC or placebo. Tics were rated at 6 visits using 5 different assessment tools: TS-CGI, STSSS, YGTSS, TSSL (self-rated), and a videotape-based rating scale.
Why This Research Matters
This was the landmark trial that moved cannabinoid treatment for Tourette syndrome from promising single-dose studies to evidence of sustained efficacy. The 6-week treatment period with multiple assessment tools and a robust study design provided the strongest evidence to date that THC could be an effective treatment for tics.
The Bigger Picture
This trial, combined with the earlier single-dose studies by the same group, established a body of randomized controlled evidence for THC in Tourette syndrome. Although larger trials have not been widely conducted, THC is now used off-label for Tourette syndrome in some clinical settings, and cannabis-based treatments continue to be investigated for this condition.
What This Study Doesn't Tell Us
The sample of 24 patients (17 completers) was still relatively small. The 29% dropout rate, while only partly due to side effects, reduces the interpretability of results. Multiple assessment tools were used, with significance reached on some but not all scales, which could raise concerns about multiple comparisons.
Questions This Raises
- ?Why have larger confirmatory trials not been conducted despite these positive results?
- ?Would higher THC doses or combined THC/CBD formulations show stronger effects?
- ?How does THC compare to conventional Tourette medications in head-to-head trials?
Trust & Context
- Key Stat:
- Significant tic reduction over 6 weeks (p=0.037) with no serious adverse effects
- Evidence Grade:
- This is a randomized, double-blind, placebo-controlled trial over 6 weeks with 24 patients, providing strong evidence as the first sustained-treatment RCT for this indication.
- Study Age:
- Published in 2003. This remains one of the most cited clinical trials for cannabinoids in Tourette syndrome.
- Original Title:
- Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.
- Published In:
- The Journal of clinical psychiatry, 64(4), 459-65 (2003)
- Authors:
- Müller-Vahl, Kirsten R(12), Schneider, Udo, Prevedel, Heidrun, Theloe, Karen, Kolbe, Hans, Daldrup, Thomas, Emrich, Hinderk M
- Database ID:
- RTHC-00143
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
How effective is THC for Tourette syndrome tics?
This 6-week trial found statistically significant tic reduction with THC compared to placebo across multiple rating scales. While the effect was not dramatic, it was consistent and achieved with good tolerability, making THC a reasonable option for patients who have not responded to conventional treatments.
Are there long-term side effects of using THC for Tourette syndrome?
This 6-week trial found no serious adverse effects, and only one patient dropped out due to side effects. However, longer-term safety data from controlled trials are limited.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00143APA
Müller-Vahl, Kirsten R; Schneider, Udo; Prevedel, Heidrun; Theloe, Karen; Kolbe, Hans; Daldrup, Thomas; Emrich, Hinderk M. (2003). Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.. The Journal of clinical psychiatry, 64(4), 459-65.
MLA
Müller-Vahl, Kirsten R, et al. "Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.." The Journal of clinical psychiatry, 2003.
RethinkTHC
RethinkTHC Research Database. "Delta 9-tetrahydrocannabinol (THC) is effective in the treat..." RTHC-00143. Retrieved from https://rethinkthc.com/research/muller-vahl-2003-delta-9tetrahydrocannabinol-thc-is
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.